Bio-IT World Conference and Expo US 2026

From molecule design and registration to first-in-human dose, the path from chemistry to clinic is ripe for earlier infusions of intelligence. What properties and bioactivity can we predict from structure alone? What could screening assays tell us about the clinical risks of off-target receptor interactions? And how can we use the combination of biosimulation and empirical PK/PD to select the optimal first-in-human dose and formulation?

At the same time, the profusion of modalities from small molecules to biomolecules to hybrids is pushing registration and compliance to become more exact and more flexible. How do we optimize those workflows so that they stay ahead of scientific discovery and evolving international regulations?